Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report
Until recently, sorafenib was the only systemic treatment available for patients with advanced hepatocellular carcinoma (HCC) since its approval in 2007. In the IMbrave150 trial, atezolizumab plus bevacizumab, as first-line therapy, demonstrated improvement in overall survival (OS) and progression-f...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://healthbook-times.scholasticahq.com/article/33919-benefits-and-complications-following-first-line-treatment-with-atezolizumab-plus-bevacizumab-in-a-patient-with-hcc-a-case-report.pdf |
| _version_ | 1828272407586013184 |
|---|---|
| author | Maria Celeste Palmarocchi Marco Cefali Antonio Galante Stefania Rizzo Sara De Dosso |
| author_facet | Maria Celeste Palmarocchi Marco Cefali Antonio Galante Stefania Rizzo Sara De Dosso |
| author_sort | Maria Celeste Palmarocchi |
| collection | DOAJ |
| description | Until recently, sorafenib was the only systemic treatment available for patients with advanced hepatocellular carcinoma (HCC) since its approval in 2007. In the IMbrave150 trial, atezolizumab plus bevacizumab, as first-line therapy, demonstrated improvement in overall survival (OS) and progression-free survival (PFS) in patients with unresectable HCC compared with sorafenib. Based on these results, this combination is recommended as a standard of care for treatment-naïve patients with advanced HCC and Child-Pugh A cirrhosis.
Earlier, we presented a review of systemic treatments for advanced HCC.^1^ Here, we reported the case of a 61-year-old patient with excellent response to the treatment with atezolizumab plus bevacizumab, despite a serious complication. |
| first_indexed | 2024-04-13T06:06:16Z |
| format | Article |
| id | doaj.art-a299ac6f95c94107b9b30524e92825d5 |
| institution | Directory Open Access Journal |
| issn | 2673-2106 |
| language | English |
| last_indexed | 2024-04-13T06:06:16Z |
| publishDate | 2022-03-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj.art-a299ac6f95c94107b9b30524e92825d52022-12-22T02:59:15ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-21062022-03-01Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case ReportMaria Celeste PalmarocchiMarco CefaliAntonio GalanteStefania RizzoSara De DossoUntil recently, sorafenib was the only systemic treatment available for patients with advanced hepatocellular carcinoma (HCC) since its approval in 2007. In the IMbrave150 trial, atezolizumab plus bevacizumab, as first-line therapy, demonstrated improvement in overall survival (OS) and progression-free survival (PFS) in patients with unresectable HCC compared with sorafenib. Based on these results, this combination is recommended as a standard of care for treatment-naïve patients with advanced HCC and Child-Pugh A cirrhosis. Earlier, we presented a review of systemic treatments for advanced HCC.^1^ Here, we reported the case of a 61-year-old patient with excellent response to the treatment with atezolizumab plus bevacizumab, despite a serious complication.https://healthbook-times.scholasticahq.com/article/33919-benefits-and-complications-following-first-line-treatment-with-atezolizumab-plus-bevacizumab-in-a-patient-with-hcc-a-case-report.pdf |
| spellingShingle | Maria Celeste Palmarocchi Marco Cefali Antonio Galante Stefania Rizzo Sara De Dosso Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report healthbook TIMES. Oncology Hematology |
| title | Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report |
| title_full | Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report |
| title_fullStr | Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report |
| title_full_unstemmed | Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report |
| title_short | Benefits and Complications Following First-Line Treatment with Atezolizumab plus Bevacizumab in a Patient with HCC: a Case Report |
| title_sort | benefits and complications following first line treatment with atezolizumab plus bevacizumab in a patient with hcc a case report |
| url | https://healthbook-times.scholasticahq.com/article/33919-benefits-and-complications-following-first-line-treatment-with-atezolizumab-plus-bevacizumab-in-a-patient-with-hcc-a-case-report.pdf |
| work_keys_str_mv | AT mariacelestepalmarocchi benefitsandcomplicationsfollowingfirstlinetreatmentwithatezolizumabplusbevacizumabinapatientwithhccacasereport AT marcocefali benefitsandcomplicationsfollowingfirstlinetreatmentwithatezolizumabplusbevacizumabinapatientwithhccacasereport AT antoniogalante benefitsandcomplicationsfollowingfirstlinetreatmentwithatezolizumabplusbevacizumabinapatientwithhccacasereport AT stefaniarizzo benefitsandcomplicationsfollowingfirstlinetreatmentwithatezolizumabplusbevacizumabinapatientwithhccacasereport AT saradedosso benefitsandcomplicationsfollowingfirstlinetreatmentwithatezolizumabplusbevacizumabinapatientwithhccacasereport |